Tech Company Financing Transactions
Exuma Biotech Funding Round
Exuma Biotech closed a $19 million Series B venture capital round on 3/13/2020. Investors included F1 BioVentures and MSD Capital.
Transaction Overview
Company Name
Announced On
3/13/2020
Transaction Type
Venture Equity
Amount
$19,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance new logic gated CAR-T therapies for solid tumor malignancies as well as for further development and partnering of its rapid point-of-care (or rPOC), same-day CAR-T platform technology.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
625 N. Flagler Dr. 625
West Palm Beach, FL 33401
USA
West Palm Beach, FL 33401
USA
Phone
Website
Email Address
Overview
EXUMA Biotechnology's mission is to provide lasting remissions via cellular therapies for patients with no other options. We are driven to achieve clinically relevant reductions in cancer mortality through industrial innovation and scientific integrity, while generating accessible solutions for patients around the world.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gregory Frost
Chief Financial Officer
James Samuels
Vice President
Bruce Yan
VP - Human Resources
Diane McCarty
VP - Operations
Wendy Zhang
VP - Product Management
Alissa Kerner
VP - R & D
Leon Zong
Browse more venture capital transactions:
Prev: 3/13/2020: Kymera Therapeutics venture capital transaction
Next: 3/13/2020: Nurix Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs